Cannabis IntoxicationCognitive functionAddictionMental healthDrugPhase 1
What this study is
This study will evaluate the subjective and behavioral effects of cannabis products labeled as indica, sativa, or generic.
What's being tested
- Cannabis
Intervention · DRUG
Cannabis will be administered via smoked inhalation.
- 0 mg THC (placebo)
Intervention · OTHER
0 mg THC (placebo)
Study details
- Sponsor
- Johns Hopkins University
- Conditions
- Cannabis Intoxication
- Enrolling
- 70 people
- Starts
- 2026-09-15
- Est. completion
- 2029-09
- Design
- Quadruple-blind, randomized, crossover, Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 21 Years – 55 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Have provided written informed consent.
- Be between the ages of 21 and 55
- Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
- Test negative for drugs of abuse including breath alcohol at the screening visit and at clinic admission
- Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. Participants must confirm use of appropriate birth control methods (e.g., condoms, birth control pills) throughout the entirety of the study.
- Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
- Have prior experience smoking cannabis but not currently using more than 3 times per week on average; participants must be active cannabis users (i.e., report past 3-month use) to participate.
You can't join if
- Self-reported use of illicit drugs (e.g., amphetamine, cocaine, methamphetamine, 3,4-Methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), ketamine, heroin, psilocybin, prescription medications not prescribed to the person) in the past 30 days.
- History of or current evidence of significant medical (e.g., seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
- History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
- Enrolled in another clinical trial or having received any drug as part of a research study within 30 days prior to dosing.
- Having previously sought medical attention to manage adverse effects following acute cannabis use
- Individuals with anemia or who have donated blood in the prior 30 days
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openJohns Hopkins University
Baltimore, Maryland, United States
- Carlos A Zamarripa, PhD · Contact410-550-6969czamarr2@jhmi.edu
Recruiting
Study team
Sponsor
Johns Hopkins University
Study ID IRB00529431
Principal investigator
Carlos A Zamarripa, PhD
Johns Hopkins University
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.